24 RS 24 RSRespiratory Syncytial Virus RS BPD24 24CHD RS RS BPD CHD
|
|
|
- たみえ にばし
- 7 years ago
- Views:
Transcription
1 Immunocompromised Children 24 RS24
2 24 RS 24 RSRespiratory Syncytial Virus RS BPD24 24CHD RS RS BPD CHD
3 RS [1] [1.1] RS 24 RS T DiGeorge Wiskott- Aldrich HIV T T PHA T TT HIV [1.2] RS 24 RS RS24 RS RS [1.3] 1224 RS 1 #1 2 #2, #3 #2 #1 0.5mg/kg/ 4 #2 #3 RS 3
4 RS RS RSBPDCLD RS , 2 BPDRS 60 3 CHD RS 4, 5 RS 6 8 RS RS 1RS R S CHD HIV Medicaid 3 1,0001Hall CB : Contemporary Pediatrics: , 1993November. 2Cunningham CK, et al : Pediatrics, 88 : , Groothuis JR, et al : Pediatrics, 82 : , McDonald NE, et al : N Engl J Med, 307 : , :, 86 : 2076, Hall CB, et al : N Engl J Med, 315 : 77-81, Meissner HC : Pediatr Infect Dis J, 222 Suppl: S40-44; discussion S44-45, Kristensen K, et al : Clin Infect Dis, 54 : , Boyce TG, et al : J Pediatr, 137 : ,
5 Drug Information CHD BPD mg/kg g/mL g/mL S.D.CHD BPD RS CHD BPD g/ml S.D. CHD BPD g/mL n=28 NA g/mL n=26 NA NA g/mL n= g/mL n= g/mL n= g/mL n= g/mL n= g/mL n= g/mL n= g/mL n=37 g/ml 0.5 mg/kg/ S.D g/mL g/mL n=4 n= g/mL g/mL n=5 n= g/mL g/mL n=8 n= g/mL g/mL n=4 n= g/mL n= g/mL n= g/mL n= g/mL n= g/mL n= g/mL n= /28 5
6 BPD 1, CHD % 1.4%1.2% RS RS ,500 5,000 4,500 4,000 3, ,000 2,500 2,000 1,500 1,
7 RS 1 RS 15mg/kg 1 1 RS 1kg15mgRS1 1mL 1 1mL kg15mg/kg 100mg/mL 2RS RS 31 RS RS RS RS RSIDWR , , RS 7
8 A187B
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
財務情報
50 Financial Information >> 52 54 66 68 69 71 72 51 2004 4,625,151 2,605,343 2,019,807 N/A 373,435 139,401 234,034 (7,603) 2005 2006 2007 2008 2008 4,664,514 4,637,657 4,769,387 6,409,727 $ 63,976 2,650,586
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
mr0511_01fix.indd
50 NOVEMBER 2005 NOVEMBER 2005 51 52 NOVEMBER 2005 NOVEMBER 2005 53 54 NOVEMBER 2005 NOVEMBER 2005 55 56 NOVEMBER 2005 NOVEMBER 2005 57 58 NOVEMBER 2005 NOVEMBER 2005 59 60 NOVEMBER 2005 NOVEMBER 2005
無印良品のスキンケア
2 3 4 5 P.22 P.10 P.18 P.14 P.24 Na 6 7 P.10 P.22 P.14 P.18 P.24 8 9 1701172 1,400 1701189 1,000 1081267 1,600 1701257 2,600 1125923 450 1081250 1,800 1125916 650 1081144 1,800 1081229 1,500 Na 1701240
! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
13 5 1 217.49 19.5 19.3 1 (10) (11) (4) 2 () 1 2 3 1 () 32 1 46 6 () 4 () (17) (74) 5 6 61 ー 7 () ( ) 8 9 10 11 12 27 31 5 13 829-1844 620-2654 669-6054 646-3054 681-6054 840-6054 856-6164 829-6124 844-7164
14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=
DeCEMBER, 17 No.34 HIV 169-73 1-1-1-13TEL 3-5937-4413:3 19:3 FAX 3-5937-443E-mail info@janpplus.jp http://janpplus.jp/!9-9-9!... 1-3 POSITIVE HIV/AIDS UNAIDS!... 4-5 JaNP+HIV Cafe Bar an opportunity...
untitled
-- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5
untitled
NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.
_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
ありがとうございました
- 1 - - 2 - - 3 - - 4 - - 5 - 1 2 AB C A B C - 6 - - 7 - - 8 - 10 1 3 1 10 400 8 9-9 - 2600 1 119 26.44 63 50 15 325.37 131.99 457.36-10 - 5 977 1688 1805 200 7 80-11 - - 12 - - 13 - - 14 - 2-1 - 15 -
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
公務員人件費のシミュレーション分析
47 50 (a) (b) (c) (7) 11 10 2018 20 2028 16 17 18 19 20 21 22 20 90.1 9.9 20 87.2 12.8 2018 10 17 6.916.0 7.87.4 40.511.6 23 0.0% 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2.0% 4.0% 6.0% 8.0%
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 A B (A/B) 1 1,185 17,801 6.66% 2 943 26,598 3.55% 3 3,779 112,231 3.37% 4 8,174 246,350 3.32% 5 671 22,775 2.95% 6 2,606 89,705 2.91% 7 738 25,700 2.87% 8 1,134
橡hashik-f.PDF
1 1 1 11 12 13 2 2 21 22 3 3 3 4 4 8 22 10 23 10 11 11 24 12 12 13 25 14 15 16 18 19 20 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 144 142 140 140 29.7 70.0 0.7 22.1 16.4 13.6 9.3 5.0 2.9 0.0
198
197 198 199 200 201 202 A B C D E F G H I J K L 203 204 205 A B 206 A B C D E F 207 208 209 210 211 212 213 214 215 A B 216 217 218 219 220 221 222 223 224 225 226 227 228 229 A B C D 230 231 232 233 A
ネットショップ・オーナー２ ユーザーマニュアル
1 1-1 1-2 1-3 1-4 1 1-5 2 2-1 A C 2-2 A 2 C D E F G H I 2-3 2-4 2 C D E E A 3 3-1 A 3 A A 3 3 3 3-2 3-3 3-4 3 C 4 4-1 A A 4 B B C D C D E F G 4 H I J K L 4-2 4 C D E B D C A C B D 4 E F B E C 4-3 4
1
1 2 3 4 5 (2,433 ) 4,026 2710 243.3 2728 402.6 6 402.6 402.6 243.3 7 8 20.5 11.5 1.51 0.50.5 1.5 9 10 11 12 13 100 99 4 97 14 A AB A 12 14.615/100 1.096/1000 B B 1.096/1000 300 A1.5 B1.25 24 4,182,500
05[ ]戸田(責)村.indd
![05[ ]戸田(責)村.indd](/thumbs/91/106164845.jpg "05[ ]戸田(責)村.indd")
147 2 62 4 3.2.1.16 3.2.1.17 148 63 1 3.2.1.F 3.2.1.H 3.1.1.77 1.5.13 1 3.1.1.05 2 3 4 3.2.1.20 3.2.1.22 3.2.1.24 3.2.1.D 3.2.1.E 3.2.1.18 3.2.1.19 2 149 3.2.1.23 3.2.1.G 3.1.1.77 3.2.1.16 570 565 1 2
/9/ ) 1) 1 2 2) 4) ) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x ) x 2 8x + 10 = 0
1. 2018/9/ ) 1) 8 9) 2) 6 14) + 14 ) 1 4 8a 8b) 2 a + b) 4) 2 : 7 = x 8) : x ) x ) + 1 2 ) + 2 6) x + 1)x + ) 15 2. 2018/9/ ) 1) 1 2 2) 4) 2 + 6 5) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x 2 15 12
2007.3„”76“ƒ
76 19 27 19 27 76 76 19 27 19 27 76 76 19 27 19 27 76 76 19 27 19 27 76 1,27, 2, 88, 8,658 27, 2,5 11,271,158 1,712,876 21,984,34 1,, 6, 7, 2, 1,78, 1,712,876 21,492,876 27, 4, 18, 11,342 27, 2,5 491,158
1631 70
70 1631 1631 70 70 1631 1631 70 70 1631 1631 70 70 1631 1631 70 70 1631 1631 70 70 1631 9,873,500 9,200,000 673,500 2,099,640 2,116,000 16,360 45,370 200,000 154,630 1,000,000 1,000,000 0 648,851 730,000
72 1731 1731 72 72 1731 1731 72 72 1731 1731 72 72 1731 1731 72 72 1731 1731 72 12,47,395 4, 735,5 1,744 4,5 97, 12,962,139 6,591,987 19,554,126 9,2, 4, 7, 2, 9,96, 6,591,987 16,551,987 2,847,395 35,5
13 21 13 3 10 2010 5 6 20 32 10 10 3 JR 14 3 1 8 2 15 6 ( ) 135 1 8 2 15 135 5 135 1 8 2 15 5 JR 135 1 8 2 15 JR 1 135 1 8 2 15 JR 135 135 135 JR 135 1 8 2 15 135 1 8
untitled
2015 2004 6 22 (1) 2 3 4 50 550 2 80 10 3 100 10 165 50 1,000 2223 2 6,800 8,400 5001,000 23 () 5 1 1 02 04 5,400 3 46 80 90 70 7090 610 02 18.2 05 22.6 1120 3,000 30 5 90 15 90 22.8 1015 80 90 1120
広報えちぜん12月号_4校.indd
24 7,140,000 24 3,129,000 24 20,685,000 24 9,292,500 24 8,925,000 24 13,492,500 24 NO. 5,670,000 24 4,470,900 24 8,494,500 24 2,341,500 24 4,021,500 Jr. [ ] 128 1214 845 855 1345 1355 2015 2025 121 127
2 3 4 5 6 7 8 ( ) 9 10 11 12 13 14 S JR 16 22 23 24 25 27 29 30 31 32 33 34 35 36 37 38 39 40 41 JR JR 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72
report_c.ai
39 182646163205 40 41 42 43 44 45 46 47 48 49 ( 50 1 2 1 P.4 2 P.5 51 50 20 52 3 4 3 P.4 4 P.5 53 JR 10 54 5 6 5 P.4 6 P.5 55 20 20 510 26 46 56 26 57 ( 510 58 26 59 ( 40 = 510 60 26 26 61 ( ( ( ) 10 62
グリセオール注インタビューフォーム
2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10
19 8 1970 20 10 4 1
19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE
MM0508佐藤.ind
51 2005 177 Zoonotic roundworm infection, with special reference to Baylisascaris procyonis larva migrans Hiroshi SATO Ascarididae Anisakidae 1 larva migrans Beaver 6, 7 7, 55, 81 Baylisascaris procyonis
1 2 2005 1983 1 ()1984 2 1947 1950 19791996 1
KEO Discussion Paper No.104 19451947 * ** 2006 11 19451947 * ** 1 2 2005 1983 1 ()1984 2 1947 1950 19791996 1 4 A A A A A 3 3 1990 19952003A2003B 4 2 198719941997 1995 1995 3 5 6 1998: 30 40 19701992 7
untitled
Contents 1. 2 2. 3 3. 7 4. 9 5. 14 6. 15 7. 17 8. 19 9. 21 1. growth hormone deficiency : GHD10,00015,000 2 2. 03 1GH T3T4 1 GHRHGHIH -CIGF-1 -CIGF-1 3 1 GHRH GHIH GH TSH LHFSH -C IGF-1 -C IGF-1 T3T4 4
137
136 137 16 12 16 17 3 18 138 8 125 144 269 9 125 144 269 10 125 144 269 11 125 144 269 12 125 143 268 13 124 146 270 14 124 147 271 15 124 149 273 16 124 149 273 17 124 152 276 4 1 3 3 3 3 3 3 8 2,641
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1